A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy.
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Cixutumumab (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Eli Lilly and Company; ImClone Systems
- 16 Aug 2010 Results published in the Journal of Clincal Oncology.
- 16 Aug 2010 Status changed from active, no longer recruiting to completed, based on an article published in the Journal of Clincal Oncology.
- 16 Aug 2010 Primary endpoint 'Objective clinical response rate' has not been met, according to an article published in the Journal of Clincal Oncology.